---
title: A Clinical Trial to Examine the Efficacy of a Supplement to Support Hormone Regulation in Women
nct_id: NCT06531668
overall_status: ACTIVE_NOT_RECRUITING
phase: NA
sponsor: Scale Media Inc
study_type: INTERVENTIONAL
primary_condition: Hormone Regulation
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06531668.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06531668"
ct_last_update_post_date: 2024-08-01
last_seen_at: "2026-05-12T06:51:16.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Clinical Trial to Examine the Efficacy of a Supplement to Support Hormone Regulation in Women

**NCT ID:** [NCT06531668](https://clinicaltrials.gov/study/NCT06531668)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Scale Media Inc
- **Collaborators:** Citruslabs
- **Conditions:** Hormone Regulation
- **Start Date:** 2024-06-07
- **Completion Date:** 2024-09-07
- **CT.gov Last Update:** 2024-08-01

## Brief Summary

This randomized, triple-blind, placebo-controlled trial will evaluate the efficacy of Live Conscious's Beyond Hormone supplement in regulating hormone production in women. The study involves 50 generally healthy female participants aged 25-45 who are not menopausal. The trial spans three menstrual cycles and assesses both objective hormone levels and subjective well-being through blood tests and questionnaires, respectively.

## Eligibility

- **Minimum age:** 25 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Female at-birth, aged 25-45.
* Not menopausal or perimenopausal.
* Regularly menstruating.
* Not taking any medication, supplement, or vitamin affecting hormone levels.
* Generally healthy and not living with any uncontrolled chronic disease.

Exclusion Criteria:

* Medical conditions or treatments affecting hormonal regulation.
* Endocrine disorders, gynecological or reproductive health conditions.
* Use of hormonal contraceptives or hormone therapy.
* Recent major illness or surgery.
* Severe allergies or hypersensitivities.
```

## Arms

- **Beyond Hormone Supplement** (EXPERIMENTAL) — Participants in this arm will receive the Beyond Hormone supplement.
- **Placebo** (PLACEBO_COMPARATOR) — Participants in this arm will receive a placebo consisting of rice flour encapsulated in a vegetable cellulose capsule.

## Interventions

- **Beyond Hormone** (DIETARY_SUPPLEMENT) — Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
- **Placebo** (OTHER) — Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.

## Primary Outcomes

- **Hormone Levels Blood Panel (estradiol, testosterone, DHEA, insulin, and progesterone)** _(time frame: Baseline (Day 0), Midline (Day 45), and Endline (Day 90))_ — Measurement of hormone levels. Blood tests will be conducted to evaluate these levels at Baseline (Day 2-5 of the first menstrual period), Midline (Day 2-5 of the second menstrual period), and Endline (Day 2-5 of the third menstrual period).

## Secondary Outcomes

- **Participants' Perceptions of Quality of Life** _(time frame: Baseline (Day 0), Midline (Day 45), and Endline (Day 90))_
- **Participants' Mood and Energy Levels using the Visual Analog Scale (VAS)** _(time frame: Baseline (Day 0), Midline (Day 45), and Endline (Day 90))_
- **Participants' Monthly Cycle Symptoms using the Menstrual Cycle Symptom Diary (MCSD)** _(time frame: Baseline (Day 0), Midline (Day 45), and Endline (Day 90))_
- **Participants' Libido using a Libido Questionnaire** _(time frame: Baseline (Day 0), Midline (Day 45), and Endline (Day 90))_

## Locations (1)

- Citruslabs, Santa Monica, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.citruslabs|santa monica|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06531668.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06531668*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*